Extraintestinal manifestations of inflammatory bowel disease

Gastroenterology and Hepatology

Volumn 7, Issue 4, 2011, Pages 235-241

  Levine, Jonathan S ^a,b   Burakoff, Robert ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Arthritis; Dermatology; Extraintestinal manifestations; Inflammotry bowel disease; Primary sclerosing cholangitis

Indexed keywords

AZATHIOPRINE; CELECOXIB; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; CYCLOPLEGIC AGENT; CYCLOSPORIN; ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; ROFECOXIB; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; APHTHOUS STOMATITIS; ARTHRALGIA; ARTHRITIS; ARTHROPATHY; BONE FRAGILITY; CHOLELITHIASIS; COMPRESSION; CONJUNCTIVITIS; CORTICOSTEROID INDUCED OSTEOPOROSIS; CORTICOSTEROID THERAPY; CROHN DISEASE; DRUG DOSE TITRATION; DRUG EFFICACY; ENTERITIS; EPISCLERITIS; ERYTHEMA NODOSUM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL LUNG DISEASE; LIVER TOXICITY; MUSCULOSKELETAL PAIN; NEPHROLITHIASIS; OBSTRUCTIVE UROPATHY; OSTEOPOROSIS; PANCREATITIS; PHYSIOTHERAPY; PORTAL VEIN THROMBOSIS; PREVALENCE; PROCTOCOLECTOMY; PSORIASIS; PYODERMA GANGRENOSUM; REVIEW; RHEUMATOID ARTHRITIS; SACROILIITIS; SCLERITIS; SPONDYLITIS; SPONDYLOARTHROPATHY; ULCERATIVE COLITIS; URINARY TRACT FISTULA; UVEITIS;

EID: 79955781336     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2001;96:1110-1122.
2. Isaacs KL. How prevalent are extraintestinal manifestations at the initial diagnosis of IBD? Inflamm Bowel Dis. 2008,14(suppl 2):S198-S199.
3. Monsén U, Sorstad J, Hellers G, Johansson C. Extracolonic diagnoses in ulcerative colitis: an epidemiological study. Am J Gastroenterol. 1990;85:711-716. (Pubitemid 20185180)
4. Aghazadeh R, Zali MR, Bahari A, Amin K, Ghahghaie F, Firouzi F. Inflammatory bowel disease in Iran, a review of 457 cases. J Gastroenterol Hepatol. 2005;20:1691-1695. (Pubitemid 43961074)
5. Schorr-Lesnick B, Brandt LJ. Selected rheumatologic and dermatologic manifestations of inflammatory bowel disease. Am J Gastroenterol. 1988;83:216-223.
6. Scarpa R, del Puente A, D'Arienzo A, et al. The arthritis of ulcerative colitis: clinical and genetic aspects. J Rheumatol. 1992;19:373-377.
7. Queiro R, Maiz O, Intxausti J, et al. Subclinical sacroiliitis in inflammatory bowel disease: a clinical and follow-up study. Clin Rheumatol. 2000;19:445-449. (Pubitemid 32041012)
8. Mahadevan U, Loftus EV Jr, Tremaine WJ, Sandborn WJ. Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. Am J Gastroenterol. 2002;97:910-914. (Pubitemid 34408247)
9. Reinisch W, Miehsler W, Dejaco C, et al. An open-label trial of the selective cyclo-oxygenase-2 inhibitor, rofecoxib, in inflammatory bowel disease-associated peripheral arthritis and arthralgia. Aliment Pharmacol Ther. 2003;17:1371-1380. (Pubitemid 36774144)
10. Fetraz MB, Tugwell P, Goldsmith CH, Atra E. Meta-analysis of sulfasalazine in ankylosing spondylitis. J Rheumatol 1990;17:1482-1486.
11. Herfarth H, Obermeier F, Andus T, et al. Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn's disease. Am J Gastroenterol. 2002;97:2688-2690.
12. American Gastroenterological Association medical position statement: guidelines on osteoporosis in gastrointestinal diseases. Gastroenterology. 2003;124:791-794.
13. Tavarela Veloso F. Review article: skin complications associated with inflammatory bowel disease. Aliment Pharmacol Ther. 2004;20(suppl 4):50-53. (Pubitemid 39319247)
14. Veloso FT, Carvalho J, Magro F. Immune-related systemic manifestations of inflammatory bowel disease A prospective study of 792 patients. J Clin Gastroenterol. 1996;23:29-34. (Pubitemid 26244497)
15. Yuksel I, Başar O, Ataseven H, et al. Mucocutaneous manifestations in inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:546-550.
16. Lofgren S. Erythema nodosum: studies on etiology and pathogenesis in 185 adults cases. Acta Med Scand. 1946;124(suppl 174):1-197.
17. Saslaw S, Beman FM. Erythema nodosum as a manifestation of histoplasmosis. JAMA. 1959;170:1178-1179.
18. Hannuksela M. Human yersiniosis: a common cause of erythematous skin eruptions. Int J Dermatol. 1977;16:665-666. (Pubitemid 8223462)
19. Soderstrom RM, Krull EA. Erythema nodosum: A review. Cutis. 1978;21:806-810.
20. Freeman HJ. Erythema nodosum and pyoderma gangrenosum in 50 patients with Crohn's disease. Can J Gastroenterol. 2005;19:603-606.
21. Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients. Medicine (Baltimore) 1976;55:401-412.
22. Lebwohl M, Lebwohl O. Cutaneous manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 1998;4:142-148. (Pubitemid 128699845)
23. Trost LB, McDonnell JK. Important cutaneous manifestations of inflammatory bowel disease. Postgrad Med J. 2005;81:580-585. (Pubitemid 41297914)
24. Thornton JR, Teague RH, Low-Beer TS, Read AE. Pyoderma gangrenosum and ulcerative colitis. Gut. 1980;21:247-248.
25. Matis WL, Ellis CN, Griffiths CE, Lazarus GS. Treatment of pyoderma gangrenosum with cyclosporine. Arch Dermatol. 1992;128:1060-1064.
26. Najarian DJ, Gottlieb AB. Connections between psoriasis and Crohn's disease. J Am Acad Dermatol. 2003;48:805-821, quiz 822-824.
27. Scarpa R, Manguso F, D'Atienzo A, et al. Microscopic inflammatory changes in colon of patients with both active psoriasis and psoriatic arthritis without bowel symptoms. J Rheumatol. 2000;27:1241-1246. (Pubitemid 30262511)
28. Lee YM, Kaplan MM. Primary sclerosing cholangitis. N Engl J Med. 1995;332:924-933.
29. Lapidus A, Bångstad M, Aström M, Muhrbeck O. The prevalence of gallstone disease in a defined cohort of patients with Crohn's disease. Am J Gastroenterol. 1999;94:1261-1266. (Pubitemid 29214639)
30. Petrelli EA, McKinley M, Troncale FJ. Ocular manifestations of inflammatory bowel disease. Ann Ophthalmol. 1982;14:356-360. (Pubitemid 12119365)
31. Das KM. Relationship of extraintestinal involvements in inflammatory bowel disease: new insights into autoimmune pathogenesis. Dig Dis Sci. 1999;44:1-13. (Pubitemid 29053071)
32. Mintz R, Feller ER, Bahr RL, Shah SA. Ocular manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2004;10:135-139. (Pubitemid 38332174)
33. Lyons JL, Rosenbaum JT. Uveitis associated with inflammatory bowel disease compared with uveitis associated with spondyloarthropathy. Arch Ophthalmol. 1997;115:61-64. (Pubitemid 27034932)
34. Suhler EB, Smith JR, Wertheim MS, et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes Arch Ophthalmol. 2005;123:903-912.
35. Banner MP. Genitourinary complications of inflammatory bowel disease. Radiol Clin North Am. 1987;25:199-209. (Pubitemid 17019050)
36. Wester AL, Vatn MH, Fausa O. Secondary amyloidosis in inflammatory bowel disease: a study of 18 patients admitted to Rikshospitalet University Hospital, Oslo, from 1962 to 1998. Inflamm Bowel Dis. 2001;7:295-300.
37. Herrlinger KR, Noftz MK, Dalhoff K, Ludwig D, Stange EF, Fellermann K. Alterations in pulmonary function in inflammatory bowel disease are frequent and persist during remission. Am J Gastroenterol. 2002;97:377-381. (Pubitemid 34160764)
38. Camus P, Piard F, Ashcroft T, Gal AA, Colby TV. The lung in inflammatory bowel disease. Medicine (Baltimore). 1993;72:151-183.
39. Spira A, Grossman R, Balter M. Large airway disease associated with inflammatory bowel disease. Chest. 1998;113:1723-1726. (Pubitemid 28307187)
40. Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology. 2003;124:795-841. (Pubitemid 36268496)